Tirzepatide in the comparison trials
The weight results are large. The comparisons establish something specific, with much of the biology still to explain.
A GIP-based peptide
Tirzepatide is a 39-amino-acid synthetic peptide built on a GIP backbone and active at GIP and GLP-1 receptors. Its C20 fatty-diacid side chain promotes albumin binding, giving it a half-life of approximately five days. The clinical reference chapter describes the dual incretin mechanism: glucose-dependent insulin release, glucagon suppression, slower gastric emptying and appetite effects.
The arithmetic implied by “dual” sounds suspect to me: two receptor names can sound like twice the effect. The receptor engagement is unequal, favouring GIP, and the precise contribution of the GIP component remains a mechanistic question. The clinical comparison is more informative than the slogan.
SURMOUNT-5 weight results
In SURMOUNT-5, 751 adults with obesity without type 2 diabetes received the maximum tolerated dose of tirzepatide or semaglutide in an open-label trial. At 72 weeks, mean body-weight change was -20.2% with tirzepatide and -13.7% with semaglutide, with P<0.001. Waist circumference also fell more with tirzepatide.
On that measured comparison, the result convinces me. They leave the participants' diagnosis, trial duration and tolerated exposure attached to the conclusion. They also leave a different question open: how much of the difference comes specifically from GIP signalling, as opposed to other pharmacological differences between the molecules?
Obesity and diabetes trials
The placebo comparison in SURMOUNT-1 involved 2,539 adults with obesity without diabetes. At the studied 15 mg dose, mean body-weight change was -20.9% at 72 weeks versus -3.1% with placebo. Gastrointestinal adverse events predominated, especially during dose escalation. That is a study dose, not a personal dosing recommendation.
The 40-week SURPASS-2 trial involved 1,879 adults with type 2 diabetes. Tirzepatide reduced HbA1c by up to 2.30 percentage points versus 1.86 with semaglutide 1 mg; all tirzepatide doses tested met noninferiority and superiority criteria. That trial’s comparator dose matters because the diabetes trial and the obesity comparison address different clinical situations.
Gallbladder and pancreatitis findings
The meta-analysis of nine randomized trials involving 9,871 participants separated two safety questions. Pancreatitis was not significantly increased versus controls: RR 1.46, 95% CI 0.59-3.61. The composite outcome of gallbladder or biliary disease was significantly increased: RR 1.97, 95% CI 1.14-3.42. Individual components of that composite did not show significant increases.
I lose useful information by combining those findings into a single reassurance or alarm. The confidence interval around pancreatitis leaves uncertainty, while the composite gallbladder finding supplies a positive safety signal. Nausea, vomiting, constipation and diarrhoea remain central tolerability issues in the obesity trial.
Appetite reports and tirzepatide warnings
People describe less food preoccupation, more energy and easier movement, but also sulfur burps, altered tastes, food aversions and frustrating weight plateaus. Such anecdotes give no controlled clinical evidence for an individual effect. The person who experiences a quieter appetite and the person who feels queasy may describe very different days despite similar weight changes.
Tirzepatide has FDA-approved formulations for type 2 diabetes, chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Compounded preparations have no FDA approval. The clinical reference discusses the thyroid C-cell tumour warning grounded in rodent data and the contraindication for a personal or family history of medullary thyroid carcinoma or MEN-2; human relevance remains unconfirmed. Hypoglycaemia risk rises with concomitant insulin or sulfonylureas. Delayed gastric emptying, lean-mass loss and weight regain after stopping are further concerns in the wider literature. After such a large appetite effect, I wonder how function and nutrition fare as weight changes.